These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 32533109)

  • 1. Passive antibody therapy in COVID-19.
    Abraham J
    Nat Rev Immunol; 2020 Jul; 20(7):401-403. PubMed ID: 32533109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Active Therapy with Passive Immunotherapy May Be Effective in the Fight against COVID-19.
    Morabito CJ; Gangadharan B
    Clin Transl Sci; 2020 Sep; 13(5):835-837. PubMed ID: 32420691
    [No Abstract]   [Full Text] [Related]  

  • 3. COVID-19 and SARS Coronavirus 2: Antibodies for the Immediate Rescue and Recovery Phase.
    Halstead SB; Akkina R
    Front Immunol; 2020; 11():1196. PubMed ID: 32574267
    [No Abstract]   [Full Text] [Related]  

  • 4. Generation of Chicken IgY against SARS-COV-2 Spike Protein and Epitope Mapping.
    Lu Y; Wang Y; Zhang Z; Huang J; Yao M; Huang G; Ge Y; Zhang P; Huang H; Wang Y; Li H; Wang W
    J Immunol Res; 2020; 2020():9465398. PubMed ID: 33134398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Passive immunotherapy with convalescent plasma against COVID-19? What about the evidence base and clinical trials?
    Garraud O
    Transfus Apher Sci; 2020 Aug; 59(4):102858. PubMed ID: 32631501
    [No Abstract]   [Full Text] [Related]  

  • 6. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model.
    Rogers TF; Zhao F; Huang D; Beutler N; Burns A; He WT; Limbo O; Smith C; Song G; Woehl J; Yang L; Abbott RK; Callaghan S; Garcia E; Hurtado J; Parren M; Peng L; Ramirez S; Ricketts J; Ricciardi MJ; Rawlings SA; Wu NC; Yuan M; Smith DM; Nemazee D; Teijaro JR; Voss JE; Wilson IA; Andrabi R; Briney B; Landais E; Sok D; Jardine JG; Burton DR
    Science; 2020 Aug; 369(6506):956-963. PubMed ID: 32540903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibodies to SARS-CoV-2 and their potential for therapeutic passive immunization.
    Klasse PJ; Moore JP
    Elife; 2020 Jun; 9():. PubMed ID: 32573433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Audio Interview: Capitalizing on Immune Responses to Covid-19.
    Rubin EJ; Baden LR; Morrissey S
    N Engl J Med; 2020 May; 382(21):e93. PubMed ID: 32433859
    [No Abstract]   [Full Text] [Related]  

  • 9. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail.
    Hansen J; Baum A; Pascal KE; Russo V; Giordano S; Wloga E; Fulton BO; Yan Y; Koon K; Patel K; Chung KM; Hermann A; Ullman E; Cruz J; Rafique A; Huang T; Fairhurst J; Libertiny C; Malbec M; Lee WY; Welsh R; Farr G; Pennington S; Deshpande D; Cheng J; Watty A; Bouffard P; Babb R; Levenkova N; Chen C; Zhang B; Romero Hernandez A; Saotome K; Zhou Y; Franklin M; Sivapalasingam S; Lye DC; Weston S; Logue J; Haupt R; Frieman M; Chen G; Olson W; Murphy AJ; Stahl N; Yancopoulos GD; Kyratsous CA
    Science; 2020 Aug; 369(6506):1010-1014. PubMed ID: 32540901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies.
    Lee WS; Wheatley AK; Kent SJ; DeKosky BJ
    Nat Microbiol; 2020 Oct; 5(10):1185-1191. PubMed ID: 32908214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2.
    Chi X; Yan R; Zhang J; Zhang G; Zhang Y; Hao M; Zhang Z; Fan P; Dong Y; Yang Y; Chen Z; Guo Y; Zhang J; Li Y; Song X; Chen Y; Xia L; Fu L; Hou L; Xu J; Yu C; Li J; Zhou Q; Chen W
    Science; 2020 Aug; 369(6504):650-655. PubMed ID: 32571838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies.
    Barnes CO; West AP; Huey-Tubman KE; Hoffmann MAG; Sharaf NG; Hoffman PR; Koranda N; Gristick HB; Gaebler C; Muecksch F; Lorenzi JCC; Finkin S; Hägglöf T; Hurley A; Millard KG; Weisblum Y; Schmidt F; Hatziioannou T; Bieniasz PD; Caskey M; Robbiani DF; Nussenzweig MC; Bjorkman PJ
    Cell; 2020 Aug; 182(4):828-842.e16. PubMed ID: 32645326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An approach towards development of monoclonal IgY antibodies against SARS CoV-2 spike protein (S) using phage display method: A review.
    Somasundaram R; Choraria A; Antonysamy M
    Int Immunopharmacol; 2020 Aug; 85():106654. PubMed ID: 32512271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody-based therapies for COVID-19: Can Europe move faster?
    Kazatchkine MD; Goldman M; Vincent JL
    PLoS Med; 2020 May; 17(5):e1003127. PubMed ID: 32369479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Convalescent Plasma: Promise for COVID-19 Pandemic.
    Sheikh S; Baig MA
    J Coll Physicians Surg Pak; 2020 Jun; 30(6):88. PubMed ID: 32723468
    [No Abstract]   [Full Text] [Related]  

  • 16. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.
    Pinto D; Park YJ; Beltramello M; Walls AC; Tortorici MA; Bianchi S; Jaconi S; Culap K; Zatta F; De Marco A; Peter A; Guarino B; Spreafico R; Cameroni E; Case JB; Chen RE; Havenar-Daughton C; Snell G; Telenti A; Virgin HW; Lanzavecchia A; Diamond MS; Fink K; Veesler D; Corti D
    Nature; 2020 Jul; 583(7815):290-295. PubMed ID: 32422645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The convalescent sera option for containing COVID-19.
    Casadevall A; Pirofski LA
    J Clin Invest; 2020 Apr; 130(4):1545-1548. PubMed ID: 32167489
    [No Abstract]   [Full Text] [Related]  

  • 18. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability.
    Brouwer PJM; Caniels TG; van der Straten K; Snitselaar JL; Aldon Y; Bangaru S; Torres JL; Okba NMA; Claireaux M; Kerster G; Bentlage AEH; van Haaren MM; Guerra D; Burger JA; Schermer EE; Verheul KD; van der Velde N; van der Kooi A; van Schooten J; van Breemen MJ; Bijl TPL; Sliepen K; Aartse A; Derking R; Bontjer I; Kootstra NA; Wiersinga WJ; Vidarsson G; Haagmans BL; Ward AB; de Bree GJ; Sanders RW; van Gils MJ
    Science; 2020 Aug; 369(6504):643-650. PubMed ID: 32540902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Convalescent serum lines up as first-choice treatment for coronavirus.
    Sheridan C
    Nat Biotechnol; 2020 Jun; 38(6):655-658. PubMed ID: 32358594
    [No Abstract]   [Full Text] [Related]  

  • 20. Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2.
    Case JB; Rothlauf PW; Chen RE; Liu Z; Zhao H; Kim AS; Bloyet LM; Zeng Q; Tahan S; Droit L; Ilagan MXG; Tartell MA; Amarasinghe G; Henderson JP; Miersch S; Ustav M; Sidhu S; Virgin HW; Wang D; Ding S; Corti D; Theel ES; Fremont DH; Diamond MS; Whelan SPJ
    Cell Host Microbe; 2020 Sep; 28(3):475-485.e5. PubMed ID: 32735849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.